Hyper Corporation

Hyper Corporation FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Hyper Corporation (065650.KQ) as of Nov 4, 2026 is 2,808.91 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 8.87 % — a change of 31,574.06% (higher).

FCF Conversion

2,808.91 %

YoY

31,574.06%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Hyper Corporation is 2025 2,808.91 % . FCF Conversion Rate (FCF/EBITDA) of Hyper Corporation was 2024 8.87 % . It decreases by 31,574.06% higher compared to the previous year.

The Hyper Corporation FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
15.67 KRW
Jan 1, 2019
244.16 KRW
Jan 1, 2020
70.26 KRW
Jan 1, 2021
68.50 KRW
Jan 1, 2022
35.23 KRW
Jan 1, 2023
126.77 KRW
Jan 1, 2024
8.87 KRW
Jan 1, 2025
2,808.91 KRW
The Hyper Corporation FCF Conversion history
YEARFCF ConversionYoY
2,808.91 %+31,574.06%
8.87 %-93.00%
126.77 %+259.88%
35.23 %-48.58%
68.50 %-2.50%
70.26 %-71.23%
244.16 %+1,457.68%
15.67 %+50.87%
10.39 %-65.07%
29.74 %+157.65%
11.54 %+3,645.35%
0.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hyper Corporation Stock analysis

What does Hyper Corporation do? Hyper Corporation Inc generates revenue through the Information Technology Business segment, which manufactures and sells mouses, monitors, televisions, routers, and game devices, while also operating Internet portals and specialized sites. The New Drug Business segment develops and sells non narcotic analgesics, Alzheimer's treatments, and Alzheimer's dementia diagnosis kits. The company's IT products are purchased by consumers and businesses seeking technology solutions, while the pharmaceutical products target healthcare providers and patients requiring pain management and cognitive health support. The Information Technology Business segment benefits from the sale of hardware devices and digital content services, with Internet portals and specialized sites driving user engagement and advertising revenue. The New Drug Business segment focuses on medical solutions for chronic conditions, serving both institutional and individual markets through direct sales channels. Both segments operate under the same corporate structure, leveraging the company's existing infrastructure for product development and distribution. Hyper Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hyper Corporation stock

FCF Conversion Rate (FCF/EBITDA) of Hyper Corporation is 2,808.91 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Hyper Corporation changed from 8.87 % to 2,808.91 %, representing a 31,574.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Hyper Corporation since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Hyper Corporation with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Hyper Corporation

All Key Metrics — Hyper Corporation